… chemoradiotherapy platforms used for head and neck cancer… Although single-agent
cisplatin-based chemoradiotherapy is … shows that multiagent-based chemoradiotherapy, and …

… The optimal cumulative dose and timing of cisplatin administration in various concurrent
chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (…

… and almost uniformly supported the superiority of concurrent chemoradiotherapy over …
chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. …

… -reported complication of chemoradiotherapy in patient with head and neck cancer. The …
cohort of patients with head and neck cancer who received concurrent chemoradiotherapy. …

… to chemoradiotherapy compared with chemoradiotherapy alone for patients with head and
neck cancer is … followed by concurrent chemoradiotherapy with cisplatin-based concurrent …

… Chemoradiotherapy-associated toxic effects that developed in treatment of head and
neck cancer reported in this study may be lower owing to the dose reduction used in the …

… of advanced head and neck cancer. However, a … chemoradiotherapy for advanced head
and neck cancer showed that RADPLAT was not superior to intravenous chemoradiotherapy. …

Background: We aimed to investigate the prognostic value of tumour-infiltrating lymphocytes’(TILs)
expression in pretreatment specimens from patients with head and neck squamous …

… chemoradiotherapy patients indicated by solid green circles. Given that one-half the patient
sample had undergone chemoradiotherapy … The demographics of the chemoradiotherapy …

… PATIENTS AND METHODS: This study was a phase II trial of chemoradiotherapy with
cisplatin 100 mg/m 2 every 28 days, infusional fluorouracil 800 mg/m 2 /d for 5 days, hydroxyurea …